SCOTTISH EVENT CAMPUS | SEC

OCT 17-20, 2024

PROGRAMME



ww.eano.eu

EANO 2024 GLASGOW, UNITED KINGDOM

19TH MEETING & EDUCATIONAL DAY OF THE EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2024 · TABLE OF CONTENT

Presidential Address	4
Board, Scientific Committee, Organisation	5
Programme Overview	6 - 9
Side Meetings	10
Poster Information	11
Save the Date EANO 2025	12
Corporate Symposia	13
Sponsors & Exhibitors	14
General Information	15 - 18
Networking Events	20 - 21
Floor Plans	22 - 24



The European Association of Neuro-Oncology gratefully acknowledges the support of the



Dear EANO members, colleagues and friends,

Welcome to the **19th Meeting of the European Association of Neuro-On-cology (EANO 2024)** and EANO's 30th anniversary celebrations in Glasgow. Glasgow is renowned for its vibrant, friendly atmosphere and its proximity to the natural beauty and grandeur of Scotland. During the meeting you will surely understand why the city has adopted 'People Make Glasgow' as its motto.

As usual, the annual EANO meeting will kick off with an Educational Day on Thursday, October 17 and the main programme will commence on Friday, October 18. The congress encourages exchange and collaboration between all relevant disciplines and aims to bring together scientific and clinical research to bridge gaps in our understanding and management of central nervous system tumours. As part of our 30-year celebrations this year we will also be including reminders of EANO's achievements with memorabilia and special events.

During the congress, speakers from across the globe will present the latest clinical trial outcomes and highlight key advances in basic and translational science. **Key themes of the Glasgow 2024 meeting** include advanced therapies, novel targets, artificial intelligence and data sharing, and quality of life issues including fertility and pregnancy. With multiple sessions organized jointly with partner organizations, there is a strong emphasis on international and interdisciplinary collaboration.

Enjoy Europe's largest neuro-oncology congress with participants from all over the world and help us celebrate our 30th birthday!

Anthony Chalmers President EANO Meeting 2024 & Susan Short EANO President





EANO Executive Board

President: Susan Short, United Kingdom President-Elect: Michael Platten, Germany Past President: Matthias Preusser, Austria Treasurer: Roberta Rudà, Italy Members: Anna Berghoff, Austria Anthony Chalmers, United Kingdom Christian Mawrin, Germany Emilie Le Rhun, Switzerland Evangelia Razis, Greece Giuseppe Minniti, Italy Lena Rosenlund, Sweden

EANO 2024 President

Anthony Chalmers, United Kingdom

EANO Scientific Committee

Chair: Manuel Valiente, Spain Past-Chair: Michael Platten, Germany Members: Anna Berghoff, Austria Anna Golebiewska, Luxemburg Anthony Chalmers, United Kingdom Antonella Castellano, Italy Asgeir Jakola, Sweden Benedikt Hasselbalch, Denmark Dieter Henrik Heiland, Germany Estela Pineda Losada, Spain Felix Sahm, Germany Franziska Ippen, Germany (Youngster Representative) Giuseppe Minniti, Italy Isabelle Ryden, Sweden (NAC Representative) Luca Tiberi, Italy Pim French, The Netherlands Susan Short, United Kingdom Tareq Juratli, Germany

EANO Congress Organiser

Scientific Management, Exhibition, Sponsorship, General Organisation and Logistics WMA GmbH Lydia Schnedl Julian Piskula T: +43 1 4051383-14 E: eano-meetings@eano.eu W: www.eano.eu/eano2024

EANO Office

Alissa McGregor Anja Bunderla c/o WMA GmbH Alser Straße 4 1090 Vienna, Austria T: +43 1 4051383-31 E: office@eano.eu W: www.eano.eu



	Educational Day Clinical track	Educational Day Basic Science track	Educational Day Nurses/AHPs track
Room/Level	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre	M4 Level 1 Meeting Academy
08.30 - 09.50	EDC01 Targeted therapy in Low Grade Gliomas	EDB01 Brain Metastases	EDN01 Radiotherapy and Patient's Profiles
09.50 - 10.00	1	TIME TO CHANGE ROOM	S
10.00 - 11.00	EDC02 How I treat?	EDB02 Neurons in carcino- genesis	EDNO2 Support needs of children and AYAs
11.00 - 11.30	1	COFFEE BREAK (HALL 5))
11.30 - 13.00	EDC03 Innovative trial design in neuro-oncology	EDB03 Liquid biopsies	EDNO3 Managing neuro- psychiatric changes
13.00 - 14.00		LUNCH BREAK (HALL 5))
14.00 - 15.20	EDC04 Imaging	EDB04 Precision medicine in neuro-oncology	EDN04 Fear of Recurrence
15.20 - 15.30	1	TIME TO CHANGE ROOM	S
15.30 - 16.30	EDC05(incl. Nurse/AHPs track) Tumour Board	EDB05 Preclinical to Clinical Translations	
16.30 - 17.00	TIME TO CHANGE ROOMS		S
17.00 - 18.00	OS01 Update on Response Assessment in Neuro- Oncology (RANO): projects and milestones	JS01 EANO-EORTC: Current Studies of the EORTC Brain Tumor Group	PC01 A clinical perspective on advanced molecular testing

FRIDAY OCTOBER 18, EANO MEETING

Index scienceKnowledge Forum10.45 - 11.15Opening and Presidential Address11.15 - 11.45Opening and Presidential Address11.45 - 13.15PLO1 Brain connectome: implications for brain tumors and their treatments13.15 - 14.45CSO1 Corporate Symposium13.30 - 14.30CSO1 Corporate Symposium14.45 - 16.15KSO2 IDH inhibitors: clinical and mole- cluar insights16.15 - 16.430CSO2 IDH inhibitors: clinical and mole- cluar insights16.15 - 16.430SO3 EXPloiting dorman- cy, senescence and their links with the immune system in brain tumors16.15 - 16.430SO3 EXPloiting dorman- cluar insights16.30 - 18.00JSO3 EANO Youngsters-16.30 - 18.00JSO3 EANO Youngsters-16.30 - 18.00SO3 EANO Youngsters-16.30 - 18.00SO3 EANO Youngsters-16.30 - 18.00May Sum					
Updates on cIMPACT-NOWMeet the EditorsPatient and Public Involvement in Brain TUNIC research09.00 - 09.15IMPACT-NOWFile TO CHAUGE ROOMS09.15 - 10.45JSO2 EANO-ESTRO: DNA repair inhibi- tors in gliomaKSO1 Boosting immune responses in the brainOSO2 Quality of Life and Symptom Manage- met: state of the scienceWSO1 EANO Career Boosting immune responses in the brainMeet the EditorsWSO1 EANO Career Boosting immune responses in the brainEANO Career Boosting immune responses in the brainMeet the EditorsWSO1 EANO Career Boosting immune responses in the brainEANO Career Boosting immune responses in the brainMeet the EditorsWSO1 EANO Career Boosting immune responses in the brain tumors and their treatmentsCOFFEE BREAK (HALL 5)EANO Career EANO Career Boosting immune responseMeet the LiditorMeet the EditorMeet the Editor13.15 - 14.45PLO1 Holi Inhibitors: clinical and mole cular insightsCSO1 Corporate SymposiumCSO2 Corporate SymposiumCSO2 Corporate SymposiumSO3 EANO 4 Navigating fertility/ pregnancy in pa- tients with primary brain tumors14.45 - 16.15KSO2 IDH inhibitors: clinical and mole cular insightsSO4 EANO-EANS: Clinical triais in surgical neuro- oncologySO4 PLO2 (16.30-17.30) Abstracts and EANO Youngsters Mentoring: Start of Something New Something New Somet	Room/Level	Ground Level	Level 1 Meeting	Ground Level SEC	Level 1 Meeting
09.15 - 10.45 09.15 - 10.45ISO2 EANO-ESTRO: DNA repair inhibi- tors in gliomaKS01 Boosting immune responses in the brainOSO2 Quality of Life and Symptom Manage ment: state of the scienceWS01 EANO Career Boost Initiative: Leadership Skills & Knowledge Forum10.45 - 11.15Opening and Presi- dential AddressCOFFEE BREAK (HALL 5)Image: ScienceImage: ScienceImage: Science11.15 - 11.45Opening and Presi- dential AddressCOFFEE BREAK (HALL 5)Image: ScienceImage: ScienceImage: Science13.15 - 14.45PLO1 Brain connectome: implications for brain tumors and their treatmentsCS01 Corporate SymposiumCS02 Corporate SymposiumCS02 Corporate SymposiumImage: ScienceImage: Science14.45 - 16.15KS02 IDH inhibitors: clinical and mole- cular insightsOS03 Exploiting dorman- typic typic typ	08.00 - 09.00	Updates on	=•=	Patient and Public Involvement in Brain	
EANO-ESTRO: DNA repair inhibi- tors in gliomaBoosting immune responses in the 	09.00 - 09.15		TIME TO CH	ANGE ROOMS	
11.15 - 11.45 (dential Address)Opening and Presi- dential Address11.45 - 13.15 Brain connectome: implications for brain tumors and their treatmentsFLO1 Brain connectome: implications for brain tumors and their treatments13.15 - 14.45CS01 Corporate SymposiumCS02 Corporate Symposium14.45 - 16.15KS02 IDH inhibitors: clinical and mole- cular insightsOS03 Exploiting dorman- cy, senescence and their links with the immune system in brain tumorsOS04 Navigating fertility/ pregnancy in pa- tients with primary brain tumours16.15 - 16.30JS03 EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult brain tumorsJS04 EANO-EANS: Clinical trials in surgical neuro- oncologyPLO2 (16.30-17.30) EANO Youngsters Mentoring: Start of Something New	09.15 - 10.45	EANO-ESTRO: DNA repair inhibi-	Boosting immune responses in the	Quality of Life and Symptom Manage- ment: state of the	EANO Career Boost Initiative: Leadership Skills &
dential Address11.45 - 13.15PLO1 Brain connectome: implications for brain tumors and their treatments13.15 - 14.4513.30 - 14.30CS01 Corporate Symposium13.30 - 14.30CS01 Corporate Symposium14.45 - 16.15KS02 IDH inhibitors: clinical and mole- clular insights16.15 - 16.30SO3 Exploiting dorman- system in brain tumors16.15 - 16.30JS03 EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult16.30 - 18.00 	10.45 - 11.15		COFFEE BRE	EAK (HALL 5)	
Brain connectome: implications for brain tumors and their treatmentsEvent StateCSO1 Corporate SymposiumCSO2 Corporate Symposium13.30 - 14.30CSO1 Corporate SymposiumCSO2 Corporate SymposiumCSO2 Corporate Symposium14.45 - 16.15KSO2 IDH inhibitors: clinical and mole- cular insightsOSO3 Exploiting dorman- cy, senescence and their links with the immune system in brain tumorsOSO4 Navigating fertility/ pregnancy in pa- tients with primary brain tumours16.15 - 16.30JSO3 EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult brain tumorsJSO4 EANO-EANS: Clinical trials in surgical neuro- oncologyPLO2 (16.30-17.30) EANO Youngsters ScholarshipsWSO2 EANO Youngsters SiOP: Uniting frontiers against pediatric and adultJSO4 EANO-EANS: Clinical trials in surgical neuro- oncologyPLO2 (16.30-17.30) EANO Youngsters ScholarshipsWSO2 EANO Youngsters SiOP: Uniting frontiers against pediatric and adultSo4 PPD1 (17.30-18.00) PPD1 (17.30-18.00) PD1 (17.30-18.00)WSO2 EANO Youngsters Scholarships	11.15 - 11.45				
13.30 - 14.30CS01 Corporate SymposiumCS02 Corporate Symposium14.45 - 16.15KS02 IDH inhibitors: clinical and mole- cular insightsOS03 Exploiting dorman- cy, senescence and their links with the immune system in brain tumorsOS04 Navigating fertility/ pregnancy in pa- tients with primary brain tumours16.15 - 16.30TIME TO CHANSE EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult brain tumorsJS04 EANO-EANS: Clinical trials in surgical neuro- oncologyPL02 (16.30-17.30) Late Breaking Abstracts and EANO-SNO ScholarshipsWS02 EANO Youngsters Mentoring: Start of Something New	11.45 - 13.15	Brain connectome: implications for brain tumors and			
14.45 - 16.15KSO2 IDH inhibitors: clinical and mole- cular insightsOSO3 Exploiting dorman- cy, senescence and their links 	13.15 - 14.45		LUNCH BRE	AK (HALL 5)	
IDH inhibitors: clinical and mole- cular insightsExploiting dorman- cy, senescence and their links with the immune system in brain tumorsNavigating fertility/ pregnancy in pa- tients with primary brain tumours16.15 - 16.30 TIME TO CHAUSE ROOMS 16.30 - 18.00 JS03 EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult brain tumors JS04 EANO-EANS: Clinical trials in surgical neuro- oncology PL02 (16.30-17.30) Late Breaking Abstracts and EANO Youngsters Mentoring: Start of Scholarships WS02 EANO Youngsters Mentoring: Start of Scholarships	13.30 - 14.30		Corporate	Corporate	
16.30 - 18.00 JS03 JS04 PL02 (16.30-17.30) WS02 EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult brain tumors JS04 EANO-EANS: Clinical trials in surgical neuro- oncology Delo2 (16.30-17.30) EANO Youngsters PHO2 (16.30-17.30) Late Breaking Abstracts and EANO-SNO Scholarships WS02 EANO Youngsters Photo: P	14.45 - 16.15	IDH inhibitors: clinical and mole-	Exploiting dorman- cy, senescence and their links with the immune system in brain	Navigating fertility/ pregnancy in pa- tients with primary	
EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult brain tumorsEANO-EANS: Clinical trials in surgical neuro- oncologyLate Breaking Abstracts and EANO-SNO ScholarshipsEANO Youngsters Mentoring: Start of Something NewPP01 (17.30-18.00) Poster Pitches IPP01 (17.30-18.00) Poster Pitches IEANO Youngsters Mentoring: Start of Something New	16.15 - 16.30	TIME TO CHANGE ROOMS			
Poster Pitches I	16.30 - 18.00	EANO Youngsters- SIOP: Uniting frontiers against pediatric and adult	EANO-EANS: Clinical trials in surgical neuro-	Late Breaking Abstracts and EANO-SNO Scholarships	EANO Youngsters Mentoring: Start of
18.00 - 19.30 Poster Viewing with authors Group A (Hall 5)					
	18.00 - 19.30	Poster Viewing with	authors Group A (Ha	III 5)	

SATURDAY OCTOBER 19, EANO MEETING

Room/Level	Lomond Auditorium Ground Level SEC Centre	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre
08.00 - 09.00	MEO4 Adaptive Trials in Neurooncology	ME05 Early diagnosis of glioma	ME06 Lipid metabolism as a therapeutic target in glioblastoma
09.00 - 09.15	1	TIME TO CHANGE ROOM	S
09.15 - 10.45	JS05 EANO-SNO: Transla- tional Advances for Meningiomas	OS05 Diagnosis, definition management, preven- tion, future research and radiation necrosis	KS03 Breaking the walls: efforts to democratize access to clinical information
10.45 - 11.15	(COFFEE BREAK (HALL 5))
11.15 - 12.45	OSO6 Highlights from clinical abstracts	OS07 Highlights from precli- nical abstracts	OS08 Advances in diagnosis and treatment of skull base tumors
12.45 - 14.15	LUNCH BREAK (HALL 5)		
13.00 - 14.00		CS03 Corporate Symposium	CS04 (13:00-13:30) Corporate Symposium
14.15 - 15.45	OS09 New target therapies in gliomas: TERT, ATRX, H3-K27M and TIM-3	OS10 Symptomatic and asymptomatic brain metastasis: consensus and implications for therapy	PCO2 EANO Youngsters: Pro-cons discussions on clinical controversies
15.45 - 16.00	١	TIME TO CHANGE ROOM	S
16.00 - 17.00	PD01 Neuro-Oncology Unplugged: A historic view on glioblastoma therapy - 30 years of EANO	JS06 EANO-EANM: Therapy of meningioma	WS03 EANO Youngsters: How to keep up with AI
17.00 - 17.15	1	TIME TO CHANGE ROOMS	S
17.15 - 17.45	PP02 Poster Pitches II		
17.15 - 18.45	Poster Viewing with auth	ors Group B (Hall 5)	

SUNDAY OCTOBER 20, EANO MEETING

Room/Level	Lomond Auditorium Ground Level SEC Centre	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre
08.00 - 09.00	EANO General Assembly		
09.00 - 10.30	KS04 Keynote Session Molecular insights into oligodendrogliomas	JS07 Joint Session EANO-EACR: Na- vigating preclinical approaches to identify windows of opportunity and develop clinical trials	OS11 Oral Session Impact of variables from the host in neuro- oncology research
10.30 - 11.00	COFFEE BREAK (HALL 5))
11.00 - 12.30	KS05 Keynote Session Cellular-based immu- notherapies	JS08 Joint Session EANO-ESNR: Progress in MR imaging for brain tumor diagnosis and monitoring	OS12 Oral Session Efforts to improve ma- nagement of incidental brain tumors
12.30 - 12.45	Closing Pomorks		

PROGRAMME CHANGES

All contents are as per date of printing (October 2, 2024).

The up-to-date scientific programme is available in the online programme on the congress website and in the congress app.

The organiser reserves the right to modify the programme in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the conference room or any other incidents during the congress which are beyond the control of the organiser.

LEGEND ABBREVIATIONS

- JS Joint Session
- KS Keynote Session
- ME Meet the Experts
- OS Oral Session
- PC Pro & Con Session
- PD Panel Discussion
- PL Plenary Session
- WS Workshop
- CS Corporate Symposium
- PP Poster Pitches



SIDE MEETINGS

All Side Meetings are closed meetings. Information as per date of printing.

THURSDAY, OCTOBER 17

Time	Meeting	Room/Floor
12.00 - 16.00	Telix Pharmaceuticals Advisory Board Meeting	Fyne / Ground Level SEC Centre
13.00 - 14.00	Biomarker Consortium	M2 / Level 1 Meeting Academy
15.30 - 16.30	EORTC Nuc Med Committee Meeting	M2 / Level 1 Meeting Academy

FRIDAY, OCTOBER 18

Time	Meeting	Room/Floor
08.00 - 09.00	WFNOS Meeting	M2 / Level 1 Meeting Academy
13.15 - 14.15	EANO Educational Committee	M4 / Level 1 Meeting Academy
13.30 - 14.30	EANO/SNO/OUP Meeting	M2 / Level 1 Meeting Academy
14.30 - 15.30	RANO-leptomeningeal metastases	M4 / Level 1 Meeting Academy
18.00 - 19.00	EANO 2024 Meet the Industry Meeting	Mezzanine / Level 1 Meeting Academy
18.15 - 19.15	Study Group Annika Malmström	M2 / Level 1 Meeting Academy
18.15 - 19.15	Curevac Investigator Meeting	M4 / Level 1 Meeting Academy
20.00 - 22.30	Nurse & Allied Health Professional Dinner Kindly supported by Novocure	Browns Restaurant Glasgow Pick up point: SEC – outside the Armadillo on Congress Road

SATURDAY, OCTOBER 19

Time	Meeting	Room/Floor
10.45 - 11.15	EANO Disparity Committee	M2 / Level 1 Meeting Academy
12.45 - 14.10	EANO SDM Working Group	M2 / Level 1 Meeting Academy
13.00 - 14.00	EANO Scientific Committee	M4 / Level 1 Meeting Academy
14.15 - 15.15	EANO Nurse & Allied Health Professional Committee (NAC)	M4 / Level 1 Meeting Academy
14.30 - 15.30	ETERNITY EORTC 1419	M2 / Level 1 Meeting Academy
17.15 - 18.15	National Societies Get-together	M4 / Level 1 Meeting Academy

POSTER PRESENTATIONS

The posters have been divided into two separate poster viewing with authors sessions. Both poster numbers for both groups will be shown on the poster board. The first poster number indicates the poster presented during the first poster session on Friday, the second poster number indicates the poster presented during the second poster session on Saturday.

SCHEDULE FOR DISPLAY, MOUNTING AND REMOVAL

Poster Viewing with authors Session I (Group A):

Friday, October 18, 18.00 - 19.30 hrs

- Posters will be on display on Friday, October 18
- Poster mounting: Friday, October 18 as of 07.30 hrs
- Poster removal: Friday, October 18 from 19.30 20.00 hrs

Poster Viewing with authors Session II (Group B):

Saturday, October 19, 17.15 - 18.45 hrs.

- Posters will be on display on Saturday, October 19
- Poster mounting: Saturday, October 19 as of 07.30 hrs
- Poster removal: Saturday, October 19 from 18.45 19.15 hrs

POSTER TOPICS

- 01. Tumor heterogeneity and plasticity
- 02. Tumor microenvironment
- 03. Cancer-Neuroscience
- 04. Metabolism
- 05. DNA damage
- 06. New targets
- 07. Sex-related influence on brain tumors
- 08. Liquid biomarkers
- 09. Imaging strategies
- 10. Artificial intelligence/Machine learning/Computational neuro-oncology
- 11. Connectome, functional neuro-on-
- cology and cognition in brain tumors 12. Immunotherapy
- 12. Immunotherapy
- 13. Radiation technologies/Radiobiology/ Radiotoxicity/Radiosensitizers
- 14. Advanced techniques in Neuro-Oncology (diagnosis and/ or treatmemt)

ABSTRACTS

Abstracts presented at the EANO 2024 are available on the congress app, the congress website and in the October digital issue of the journal "NeuroOncology".

- 15. Multilayer diagnostics 16. Pediatric brain tumors
- 17. Brain metastasis and
- leptomeningeal disease 18. Adult glioma
- 19. Meningioma
- 20. Rare CNS tumors
- 20. Rare CNS turnors 21. Other tumor entities
- 21. Other turnor entities
- 22. QoL/Palliative care, end of life and care giving
- 23. Symptoms and symptom management
- 24. Patient and public involvement
- 25. Epidemiology/ Biobanks/ National registries
- 26. Preclinical neuro-oncology (not covered by other topics)
- 27. Clinical neuro-oncology

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY EANO 2025 PRAGGUE

Prague Congress Center • Prague, Czech Republic



EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY WWW.EANO.EU

20TH MEETING & EDUCATIONAL DAY OCTOBER 16-19, 2025

EANO 2024 · CORPORATE SYMPOSIA

OVERVIEW OF CORPORATE SYMPOSIA

FRIDAY, OCTOBER 18

Time	Title	Company	Room / Level
13.30 - 14.30	Multidisciplinary clinical management of diffuse glioma patients: Is it still the era of watch & wait?**	Servier	M1 / Level 1 Meeting Academy
13.30 - 14.30	Real World Evidence: 10 Years of Experience Treating High Grade Glioma with Tumor Treating Fields (TTFields) Therapy**	Novocure	Alsh / Ground Level SEC Centre

SATURDAY, OCTOBER 19

Time	Title	Company	Room / Level
13.00 - 14.00	Development of IGV-001 for the treat- ment of newly diagnosed glioblastoma**	Imvax	M1 / Level 1 Meeting Academy
	LITT* as a surgical minimally invasive treatment option in neuro-oncology (*Laser Interstitial Thermal Therapy)	Medtronic	Alsh / Ground Level SEC Centrer

**Lunch boxes will be provided to session attendees.



ENROLLMENT COMPLETED

NOW ENROLLING

Phase 2b study of IGV-001 in patients with newly diagnosed glioblastoma (**NCT04485949**)

Learn More: www.clinicaltrials.gov/study/NCT04485949 www.imvax.com/patients-families

SPONSORS

Platinum Sponsor



CHIMERIX **NOVCUICE**

Silver Sponsor



SERVIER

General Sponsors

Carthera	
Focused Ultrasound Foundation	

Curevac Novartis - Advanced Accelerator **Applications International**

EXHIBITORS

BRAIN UK	Cercare Medical
Chimerix	Dxcover
Fore Biotherapeutics	Medtronic
Novocure	SERB
Servier	Standard BioTools
Tessa Jowell Brain Cancer Mission	The Brain Tumour Charity
VectorBuilder	VPIX Medical
European Association of Neuro-Oncology (EANO)	

GENERAL INFORMATION

Opening hours

Registration

Hall 5, Ground Level SEC Centre

Wednesday, October 16, 2024	16.00 – 19.00 hrs
Thursday, October 17, 2024	07.30 – 18.30 hrs
Friday, October 18, 2024	07.30 – 19.00 hrs
Saturday, October 19, 2024	07.30 – 18.00 hrs
Sunday, October 20, 2024	07.30 – 11.30 hrs

Speaker Service Centre

M3, Level 1 Meeting Academy

Wednesday, October 16, 2024	16.00 – 19.00 hrs
Thursday, October 17, 2024	07.30 – 18.00 hrs
Friday, October 18, 2024	07.30 – 18.00 hrs
Saturday, October 19, 2024	07.30 – 17.00 hrs
Sunday, October 20, 2024	07.30 – 10.00 hrs

Exhibition

Hall 5, Ground Level SEC Centre

Thursday, October 17, 2024	09.30 – 17.30 hrs
Friday, October 18, 2024	09.00 – 19.30 hrs
Saturday, October 19, 2024	09.00 – 18.45 hrs
Sunday, October 20, 2024	CLOSED

Poster Area

Hall 5, Ground Level SEC Centre

Thursday, October 17, 2024	CLOSED
Friday, October 18, 2024	08.00 - 19.30 hrs
Saturday, October 19, 2024	08.00 - 18.45 hrs
Sunday, October 20, 2024	CLOSED

Cloakroom

Hall 5, Ground Level SEC Centre

Thursday, October 17, 2024	07.30 – 18.30 hrs
Friday, October 18, 2024	07.30 – 20.00 hrs
Saturday, October 19, 2024	07.30 – 19.00 hrs
Sunday, October 20, 2024	07.30 – 13.15 hrs

Discover the clinical evidence of Optune Gio®

VISIT BOOTH #11

Optune Gio is a CE marked medical device (CE-0197).

Indication

Newly diagnosed WHO grade 4 glioma.

Optune Gio is intended for the treatment of adult patients (18 years of age or older) with newly diagnosed WHO grade 4 glioma, following maximal debulking surgery or biopsy, radiation therapy and/or chemotherapy, concomitant with maintenance Temozolomide with or without Lomustine, and after systemic therapy is stopped.

Contraindications

Do not use the Optune Gio treatment kit if you are pregnant, think you might be pregnant, or are trying to get pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. The Optune Gio treatment kit was not tested in pregnant women.

Do not use the Optune Gio treatment kit if you have significant additional neurological disease (primary seizure disorder, dementia, Progressive degenerative neurological disorder, Meningitis or encephalitis, Hydrocephalus associated with increased intracranial pressure). Do not use the Optune Gio treatment kit if you are known to be sensitive to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with the Optune Gio treatment kit may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Do not use Optune Gio if you have an active implanted medical device, a skull defect (such as, missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers and defibrillators. Use of the Optune Gio treatment kit together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device. Use of the Optune Gio treatment kit together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render treatment ineffective.

The most common device specific adverse event was mild to moderate skin irritation under the arrays.

For more information on the indication, contraindications, warnings, notices and precautions, please read the product specific User Manual: https://manuals.novocure.eu/

novœure

©2024 Novocure GmbH. All Rights Reserved. Optune Gio and Novocure are trademarks of Novocure GmbH. GB-OPG-00014 v1.0 September 2024

EANO 2024 · GENERAL INFORMATION

Location and Accessibility



Congress Venue Scottish Event Campus | SEC

Glasgow G3 8YW United Kingdom WIFI Network: EANO2024 Password: eano2024UK

www.sec.co.uk/

Public transport

The SEC has its own dedicated railway station – Exhibition Centre – allowing easy access from the city centre and suburbs. There are six trains an hour (around every 10 minutes) from Glasgow Central station, departing from Platform 17 (low level). From Queen Street, you'll need to walk or get a bus to Central to continue your journey by train.

Strathclyde Passenger Transport operates the Glasgow Subway providing quick and convenient connections from 15 points across the city (the St. Enoch stop is a few minutes' walk from Central Station for onward transfer to the SEC).

Glasgow Conference Rover Ticket: Issuead at a flat price of £5 at all ScotRail stations within the Conference Zone to conference delegates showing qualifying identification: conference badge OR registration confirmation with ID. The ticket is valid within Glasgow city centre for five days unlimited rail travel on all ScotRail services within the Conference Zone.

Glasgow

For information about Glasgow, visit the congress website: https://www.eano.eu/ eano2024/myconference/location-venue/#glasgow

Conference Policy

Badges

Admission to the congress (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire congress is mandatory!

Language

The official language of the congress is English (no simultaneous translation available).

CME Credits

The 19th Meeting of the European Association of Neuro-Oncology, Glasgow, United Kingdom 17/10/2024 - 20/10/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **23.5** European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



To receive CME credits participants must scan their badge every day at the registration desk. After completion of the post-congress survey sent by email, participants will be able to download their personalised certificate of attendance (incl. CME credits) and/or have it sent to their email address. The certificate of attendance will indicate the number of CME credits that correspond with the badge scans.

Note: If a participant misses to scan the badge no credits will be accredited for that day.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Certificate of attendance

Confirmations of attendance will be issued via email to all participants after the congress.

Catering

During the morning **coffee breaks**, refreshments (coffee, tea and snacks) will be served free of charge to participants wearing name badges in the exhibition area.

During the **lunch breaks**, a light lunch as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area.

Additionally, water will be provided for free on all floors and coffee will be provided during the day in the exhibition area.

Smoking Policy

The EANO 2024 is officially a "no-smoking-congress".

Sustainability

The EANO is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organizer therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking events, bringing your own water bottle to the congress and by using the existing possibilities for waste separation.



RESEARCH GRANT

- Supporting high-quality projects in the field of neuro-oncology
- Available funding: up to 50,000 EUR
- Submission deadline: January 23, 2025



 $(\mathbf{f})(\mathbb{X})(\mathbf{0})(\mathbf{\hat{s}})(\mathbf{\hat{n}})$



www.eano.eu

NICE TO MEET YOU!

Please note that the number of participants for all networking events is limited and advance registration is mandatory for each event. Check ticket availability at the registration desk.

Admission will only be granted with a valid ticket. For the Welcome Reception and EANO Evening bring your congress badge to be scanned at the entrance.

Welcome Reception - Civic Reception

Location: Glasgow Science Centre Date: Thursday, October 17, 2024 Time: 18.30 – 21.00 hrs



Address: 50 Pacific Quay, Glasgow G51 1EA 4 minutes walking distance from the SEC *Individual arrival.*

Spend a nice networking evening with your colleagues in a relaxed atmosphere while enjoying finger food and drinks. The Civic Reception courtesy of The Rt Hon The Lord Provost of Glasgow and Glasgow City Council is free of charge, however admission is only possible for pre-registered participants.

Dresscode: casual



The EANO acknowledges and is grateful for the support of the Lord Provost and the City Council of Glasgow.

Youngsters Networking Night

Location: Van Winkle West End Date: Friday, October 18, 2024 Time: 20.00 - 24.00 hrs



Address: 23 Sandyford PI, Glasgow G3 7NG Public transport: Bus 3 or 77 station Elderslie Street or bus 100 station Argyle Street opp Berkeley Street *Individual arrival.*

Join the EANO Youngsters Networking Night and socialise with other young scientists. You can expect a relaxed atmosphere among other young colleagues from Europe and the world (age <36) with snacks and drinks (3 drinks are included in the price).

Dresscode: casual

No sponsoring is used to fund any part of the evening.

Career Booster Initiative Networking

Location: The Exchange Date: Friday, October 18, 2024 Time: 20:00-24:00 hrs



21

Address: 29 Royal Exchange Square, Glasgow, G1 3AJ

Public transport: Train stations Queen Street and Glasgow Central, Bus station Buchanan Individual arrival.

Join the excitement at the EANO Career Boost Initiative (CBI) social event! Tailored specifically for physicians and researchers striving for independence, this event is the perfect opportunity to forging meaningful connections and igniting fresh, innovative ideas. Highlighting the evening is an engaging workshop focused on enhancing your scientific communication skills, designed to turbocharge your networking potential. Tickets include free drinks and finger food.

Dresscode: casual

Kindly supported by Ailse Oncology, Blue Earth Diagnostics, Nervianoms, Servier Nederland, TheraCryf

EANO Evening

Location:Kelvingrove Art Gallery & MuseumDate:Saturday, October 19, 2024Time:19.30 – 23.30 hrs



Address: Argyle St, Glasgow G3 8AG, United Kingdom Public transport:

The bus stops at the front of Kelvingrove, on Argyle Street, have regular services from both directions. Services include: First Bus- services 2, 3 & 77; McGill's - service 17. The closest Subway station is Kelvinhall. *Individual arrival.*


Spend a wonderful evening with your colleagues and friends from around the world. You will be able to enjoy dinner and drinks together with music in an authentic atmosphere.

Dresscode: casual

No sponsoring is used to fund any part of the evening.

SonoBird Trial

SonoCloud-9 in association with carboplatin vs standard-of-care in rGBM




LEARN MORE This pivotal, multi-site trial, conducted across Europe and the United





States, is an open-label, randomized study aimed at evaluating and comparing survival outcomes in 560 patients. Participants, all candidates for resection, will either receive a SonoCloud[®] implant with repeated BBB opening in combination with carboplatin, or undergo standard-of-care chemotherapy. (NCT05902169)

www.sonobird.eu












25



1	IBTA	4	Cercare Medical	7	VPIX Medical	10	Servier	13	Chimerix
2	The Brain Tumour Charity	5	Standard BioTools	8	BRAIN UK	11	Novocure	15	Medtronic
3	Tessa Jowell Brain Cancer Mission	6	Dxcover	9	Vector Builder	12	SERB	16	Fore Biotherapeutics

The ACTION Study

Dordaviprone (ONC201) in newly diagnosed H3 K27M-mutant diffuse glioma



- The H3 K27M mutation occurs in both pediatric and adult patients with glioma^{1,2}
- Dordaviprone, a first-in-class imipridone, is a selective small molecule agonist of CIpP and antagonist of DRD2

The ACTION study (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group international Phase 3 trial of patients with newly diagnosed, H3 K27M diffuse glioma after completion of radiotherapy.

Eligibility Criteria

- H3 K27M-mutant diffuse glioma, H3 K27M mutation by IHC or NGS
- ≥10 kg body weight
- Completed radiotherapy within 2 to 6 weeks prior to randomization
- KPS/LPS ≥70
- Stable or decreasing corticosteroids and anti-seizure medication for seven days
- Not eligible: Spinal tumors, DIPG, leptomeningeal spread, CSF dissemination



Primary Outcomes:

• Efficacy: OS, PFS

Study Status:

- ACTION is enrolling at more than 140 centers throughout the USA, Europe, Israel, and Asia-Pacific, with additional sites planned.
- An up-to-date list of study sites is available at clinicaltrials.gov (NCT05580562).
- Funding is available for eligible patients who must travel for treatment; contact clinicaltrials@chimerix.com for more information.

Dordaviprone is an investigational drug currently undergoing clinical development and has not been approved for sale by regulatory health authorities.

Visit us at Booth 13



References

1. Lulla RR, et al. *Sci Adv.* 2016;2(3):e1501354 2. Khuong-Quang DA, et al. *Acta Neuropathol.* 2012;124(3):439-47



chimerix.com

30 YEARS OF EXCELLENCE



#HappyBirthdayEANO

Leave your congratulations to EANO!

What do you wish for the EANO? What do you hope for the future of neuro-oncology? Write to us in our guestbook on www.30.eano.eu or on social media and use *#HappyBirthdayEANO*.

We look forward to hearing from you!